BICO's Calendar for financial reporting: H2 2024 and 2025
October 18, 2024 at 01:05 am EDT
Share
English
Swedish
Published: 2024-10-18 07:00:00 CEST
BICO Group AB
Financial Calendar
BICO's Calendar for financial reporting: H2 2024 and 2025
BICO Group AB 559050-5052 (NASDAQ STOCKHOLM: BICO)
BICO's Calendar for financial reporting: H2 2024 and 2025
Q3 report 2024: November 26, 2024, 7am CET
Year-end report 2024: February 19, 2025, 7am CET
Annual Report 2024: March 20, 2025, to be released during the day
Q1 report 2025: April 29, 2025, 7am CEST
Annual General Meeting 2025: May 8, 2025. Time to be announced in notice to AGM 2025
Q2 report 2025: August 19, 2025, 7am CEST
Q3 report 2025: November 4, 2025, 7am CET
Year-end report 2025: February 10, 2026, 7am CET
Please note that, as communicated during the Capital Markets Day and due to the new business area structure, BICO's Q3 report 2024 will be released on Tuesday November 26, 2024, at 7am CET.
For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com
The information was submitted for publication, through the agency of the contact person set out above, on October 18, 2024 at 7am CEST.
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 46,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 12,000 publications. Operating through three business areas - Lab Automation, Life Science Solutions, and Bioprinting - BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
Attachments:
BICOs Calendar for financial reporting H2 2024 and 2025.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original document
Permalink
Disclaimer
BICO Group AB published this content on October 18, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on October 18, 2024 at 05:04:07.511.
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Companyâs operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
